Northwire Canada EditionThursday, October 15, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4% GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4%
Other

NuGen Files Patent for Ready-to-Fill COP/COC Needle-Free Injection Nozzle, Advancing Prefilled Nozzle Technology

NuGen Files Needle-Free Nozzle Patent as Stock Tests Multi-Year Lows

By The Northwire Desk — AI Analysis Mar 25, 2026 · 17:15 NGMD · 0.025 Nugen Medical Devices Inc.
Executive Summary
  • NuGen Medical Devices filed a patent for a Ready-to-Fill (RTF) COP/COC injection nozzle, branded as the Prefilled Nozzle (PFN) platform.
  • The PFN is designed for needle-free, high-pressure jet injection of complex biologics (GLP-1s, growth hormones, monoclonal antibodies) and is compatible with standard aseptic fill-finish lines.
  • The system pairs the disposable nozzle with a reusable auto-injector that automatically adjusts to 0.5 mL or 1.0 mL formats and delivers the full dose in under one second.
  • NuGen has partnered with Gerresheimer Medical Plastics to utilize fully automated RTF production lines, aiming to minimize manufacturing changes for pharma partners.
  • Pre-clinical testing of PFN samples is targeted for completion by year-end 2026, with a fixed-dose auto-injector launch planned for 2027.
  • Management highlights ESG benefits, reduced drug waste, elimination of needle-stick injuries, and avoidance of needle-lumen chemical interactions as key value propositions for potential pharmaceutical partners.
Material Impact
  • The patent filing represents an incremental R&D milestone rather than a near-term commercial catalyst. It extends NuGen's existing needle-free portfolio but does not generate immediate revenue or alter the current commercial trajectory of the InsuJet or EziAutoJector products.
  • The timeline to commercialization (pre-clinical by late 2026, product launch in 2027) introduces significant execution and regulatory risk. The market has already priced in early-stage development uncertainty, as evidenced by the stock's prolonged downtrend.
  • The Gerresheimer partnership is strategically sound for manufacturing scalability, but it does not guarantee pharma adoption or licensing deals. The news is positive for long-term pipeline diversification but routine in the context of medtech development cycles.
  • No immediate financial impact, dilution event, or regulatory approval is attached to this release. The announcement aligns with the company's stated 2025-2026 R&D roadmap.
NGMD · Price
Company Overview
  • NuGen Medical Devices develops and commercializes needle-free drug delivery systems.
  • Flagship commercial product: InsuJet, a needle-free insulin delivery system approved in 42 countries.
  • UK commercial partner: EziAutoJector Ltd., which recently secured NHS drug tariff approval for reimbursable dispensing of its needle-free insulin device and accessories.
  • Pipeline: Prefilled Nozzle (PFN) platform targeting high-viscosity biologics, currently in pre-clinical development with a 2027 commercial launch target.
  • The company operates in a highly competitive medical device space, relying on clinical differentiation, regulatory approvals, and strategic manufacturing partnerships to scale.
Read the original news release →

More from Nugen Medical Devices Inc.

May 28, 2026 · 13:44

Micro-cap device firm advances IP portfolio amid regulatory headwinds

M&A / Property Mar 26, 2026 · 04:16

Nugen files patent for needle-free injection nozzle

Other Feb 05, 2026 · 17:16

NuGen Medical Devices Inc. Provides Update on Health Canada License

Production / Operations Jan 16, 2026 · 18:36

Nugen looks back at 2025 R&D programs

Production / Operations Jan 16, 2026 · 17:31

NuGen Medical Devices Provides 2025 Year End Update on R&D and Strategic Progress

Production / Operations